DE69721258D1 - Markierung und auswahl von molekülen - Google Patents

Markierung und auswahl von molekülen

Info

Publication number
DE69721258D1
DE69721258D1 DE69721258T DE69721258T DE69721258D1 DE 69721258 D1 DE69721258 D1 DE 69721258D1 DE 69721258 T DE69721258 T DE 69721258T DE 69721258 T DE69721258 T DE 69721258T DE 69721258 D1 DE69721258 D1 DE 69721258D1
Authority
DE
Germany
Prior art keywords
molecules
marker ligand
sbp member
sbp
specific binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69721258T
Other languages
English (en)
Other versions
DE69721258T2 (de
Inventor
Katharine Osbourn
Joy Derbyshire
Gerald Mccafferty
John Vaughan
Stuart Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune Ltd
Original Assignee
Cambridge Antibody Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9614292.2A external-priority patent/GB9614292D0/en
Application filed by Cambridge Antibody Technology Ltd filed Critical Cambridge Antibody Technology Ltd
Publication of DE69721258D1 publication Critical patent/DE69721258D1/de
Application granted granted Critical
Publication of DE69721258T2 publication Critical patent/DE69721258T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70542—CD106
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/535—Production of labelled immunochemicals with enzyme label or co-enzymes, co-factors, enzyme inhibitors or enzyme substrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69721258T 1996-07-08 1997-07-08 Markierung und auswahl von molekülen Expired - Lifetime DE69721258T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9614292.2A GB9614292D0 (en) 1996-07-08 1996-07-08 Labelling and selection of specific binding molecules
GBGB9624880.2A GB9624880D0 (en) 1996-07-08 1996-11-29 Labelling and selection of specific binding molecules
GBGB9712818.5A GB9712818D0 (en) 1996-07-08 1997-06-18 Labelling and selection of specific binding molecules
PCT/GB1997/001835 WO1998001757A1 (en) 1996-07-08 1997-07-08 Labelling and selection of molecules

Publications (2)

Publication Number Publication Date
DE69721258D1 true DE69721258D1 (de) 2003-05-28
DE69721258T2 DE69721258T2 (de) 2004-01-29

Family

ID=27268364

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69735686T Expired - Lifetime DE69735686T2 (de) 1996-07-08 1997-07-08 Markierung und Auswahl von Molekülen
DE69721258T Expired - Lifetime DE69721258T2 (de) 1996-07-08 1997-07-08 Markierung und auswahl von molekülen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69735686T Expired - Lifetime DE69735686T2 (de) 1996-07-08 1997-07-08 Markierung und Auswahl von Molekülen

Country Status (8)

Country Link
US (4) US5994519A (de)
EP (1) EP0906571B1 (de)
AT (1) ATE238550T1 (de)
AU (1) AU715796B2 (de)
CA (1) CA2259421C (de)
DE (2) DE69735686T2 (de)
GB (3) GB9712818D0 (de)
WO (1) WO1998001757A1 (de)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2247204T3 (es) 1994-01-31 2006-03-01 Trustees Of Boston University Bancos de anticuerpos policlonales.
US20060078561A1 (en) * 1994-01-31 2006-04-13 The Trustees Of Boston University Polyclonal antibody libraries
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US20030044772A1 (en) * 1997-08-04 2003-03-06 Applied Molecular Evolution [Formerly Ixsys] Methods for identifying ligand specific binding molecules
US6171802B1 (en) * 1998-06-10 2001-01-09 Kent State University Detection and amplification of ligands
FR2783528A1 (fr) * 1998-08-28 2000-03-24 Commissariat Energie Atomique Procede de synthese d'une chimiokine marquee, chimiokine marquee et trousse d'analyse
WO2000012554A1 (fr) * 1998-08-28 2000-03-09 Commissariat A L'energie Atomique Procede de synthese d'une chimiokine marquee, chimiokine marquee et trousse d'analyse
US6335173B1 (en) * 1999-01-12 2002-01-01 Verve, Ltd. C/O James Bell Methods for detecting an analyte of interest using tyramide coating technology
US6280961B1 (en) 1999-05-25 2001-08-28 Verve, Ltd. Use of tyramide coating and physical separation for isolating cells or particles of interest
US6903196B1 (en) 1999-06-17 2005-06-07 Utah Ventures Ii, L.P. Methods for identifying and isolating tissue-specific lumen-exposed molecules
AU6054900A (en) * 1999-06-26 2001-01-31 Odyssey Pharmaceuticals, Inc. An in vivo library-versus-library selection of optimized protein-protein interactions
US7304127B2 (en) 1999-08-27 2007-12-04 United States Of America As Represented By The Secretary, Department Of Health And Human Services Polypeptides that bind HIV gp120 and related nucleic acids, antibodies, compositions, and methods of use
AU6941000A (en) * 1999-08-27 2001-03-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Polypeptides that bind hiv gp120 and related nucleic acids, antibodies, compositions, and methods of use
AU2001253589B2 (en) * 2000-04-17 2007-08-16 Dyax Corp Methods of constructing display libraries of genetic packages for members of a diverse family of peptides
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
CA2412150A1 (en) * 2000-07-12 2002-01-17 Gryphon Therapeutics, Inc. Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use
EP1360488B1 (de) * 2000-07-26 2016-04-13 ChemoMetec A/S Enzymgebundener assay mit räumlicher auflösung
AUPQ937100A0 (en) * 2000-08-15 2000-09-07 Food & Packaging Centre Management Limited Odour sensor
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
PL365671A1 (en) * 2000-09-08 2005-01-10 Gryphon Therapeutics, Inc. Synthetic erythropoiesis stimulating proteins
CN1394282A (zh) * 2000-10-31 2003-01-29 新澙大学校长代表的日本国 诊断精神分裂症的药物试剂盒
US20030119056A1 (en) 2000-12-18 2003-06-26 Ladner Robert Charles Focused libraries of genetic packages
DE60237282D1 (de) * 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
US20040077835A1 (en) * 2001-07-12 2004-04-22 Robin Offord Chemokine receptor modulators, production and use
US20050069962A1 (en) * 2001-10-12 2005-03-31 Archer Robert M Antibody complexes and methods for immunolabeling
US8323903B2 (en) 2001-10-12 2012-12-04 Life Technologies Corporation Antibody complexes and methods for immunolabeling
US6844029B2 (en) * 2001-10-26 2005-01-18 Kansai Paint Co., Ltd. Photocurable primer composition and coating method by use of the same
WO2003072542A2 (en) * 2001-11-20 2003-09-04 Duke University Interfacial biomaterials
US7253007B2 (en) * 2001-11-30 2007-08-07 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7442512B2 (en) * 2001-11-30 2008-10-28 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7871619B2 (en) * 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US7413866B2 (en) * 2001-11-30 2008-08-19 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
US20040210289A1 (en) * 2002-03-04 2004-10-21 Xingwu Wang Novel nanomagnetic particles
IL163725A0 (en) 2002-02-25 2005-12-18 Elan Pharm Inc Administration of agents for the treatment of inflammation
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US9701754B1 (en) 2002-10-23 2017-07-11 City Of Hope Covalent disulfide-linked diabodies and uses thereof
AU2003277832A1 (en) * 2002-10-31 2004-05-25 Novo Nordisk A/S Humanized tissue factor antibodies
DK1572106T3 (da) 2002-11-15 2010-08-23 Novartis Vaccines & Diagnostic Fremgangsmåde til forebyggelse og behandling af cancermetastase og knogletab forbundet med cancermetastase
KR101061352B1 (ko) * 2002-12-20 2011-08-31 케모센트릭스 인간 종양-발현된 ｃｃｘｃｋｒ2의 저해물질
MXPA05007823A (es) 2003-01-24 2005-10-18 Elan Pharm Inc Composicion y tratamiento de enfermedades desmielizantes y paralisis por administracion de agentes remielinizantes.
US20050079132A1 (en) * 2003-04-08 2005-04-14 Xingwu Wang Medical device with low magnetic susceptibility
US20040254419A1 (en) * 2003-04-08 2004-12-16 Xingwu Wang Therapeutic assembly
US20070010702A1 (en) * 2003-04-08 2007-01-11 Xingwu Wang Medical device with low magnetic susceptibility
US20050025797A1 (en) * 2003-04-08 2005-02-03 Xingwu Wang Medical device with low magnetic susceptibility
US7321065B2 (en) * 2003-04-18 2008-01-22 The Regents Of The University Of California Thyronamine derivatives and analogs and methods of use thereof
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
US20100247540A1 (en) * 2003-10-30 2010-09-30 Chemocentryx, Inc. Methods and Compositions For Modulating Angiogenesis
PT1704166E (pt) 2004-01-07 2015-09-04 Novartis Vaccines & Diagnostic Anticorpo monoclonal específico de m-csf e respetivos usos
SI1835922T1 (sl) * 2004-12-22 2009-10-31 Merck Serono Sa Kombinacijsko zdravljenje multiple skleroze
CA2589860A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
PL1871804T3 (pl) * 2005-04-21 2014-01-31 Chemocentryx Inc Przeciwciała wiążące CCX-CKR2
EP1913028B1 (de) * 2005-07-28 2015-03-04 Novartis AG Anwendung von antikörpern gegen m-csf
US8652469B2 (en) * 2005-07-28 2014-02-18 Novartis Ag M-CSF-specific monoclonal antibody and uses thereof
JP2009529915A (ja) 2006-03-20 2009-08-27 ゾーマ テクノロジー リミテッド ガストリン物質に対して特異的なヒト抗体および方法
EP1996716B1 (de) 2006-03-20 2011-05-11 The Regents of the University of California Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
EP2420252A1 (de) * 2006-08-04 2012-02-22 Novartis AG EPHB3-spezifischer Antikörper und Verwendungen davon
TWI454480B (zh) * 2006-08-18 2014-10-01 Novartis Ag 催乳激素受體（ｐｒｌｒ）之專一性抗體及其用途
US8377439B2 (en) 2006-12-07 2013-02-19 Novartis Ag Antagonist antibodies against EPHB3
RU2554747C9 (ru) 2006-12-20 2015-10-20 Ксома (Сша) Ллс Способы лечения il-1бета-зависимых заболеваний
WO2008097461A2 (en) * 2007-02-02 2008-08-14 Amgen Inc Hepcidin and hepcidin antibodies
WO2009032949A2 (en) 2007-09-04 2009-03-12 The Regents Of The University Of California High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
US8263078B2 (en) * 2007-09-05 2012-09-11 Inotek Pharmaceuticals Corporation Antibodies against flagellin and uses thereof
BRPI0816785A2 (pt) 2007-09-14 2017-05-02 Adimab Inc bibliotecas de anticorpos sintéticos racionalmente desenhadas, e, usos para as mesmas
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP2209498A2 (de) * 2007-10-03 2010-07-28 Cornell University Behandlung von proliferativen erkrankungen mit psma-antikörpern
CA2710252C (en) 2007-12-20 2017-03-28 Xoma Technology Ltd. Methods for the treatment of gout
WO2009085200A2 (en) 2007-12-21 2009-07-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
WO2009094551A1 (en) 2008-01-25 2009-07-30 Amgen Inc. Ferroportin antibodies and methods of use
US9873957B2 (en) 2008-03-13 2018-01-23 Dyax Corp. Libraries of genetic packages comprising novel HC CDR3 designs
CA2968164C (en) 2008-04-24 2019-08-20 Dyax Corp. Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
ES2487846T3 (es) 2008-05-01 2014-08-25 Amgen, Inc. Anticuerpos anti-hepcindina y métodos de uso
US20100069616A1 (en) * 2008-08-06 2010-03-18 The Regents Of The University Of California Engineered antibody-nanoparticle conjugates
CA2733642A1 (en) 2008-08-14 2010-02-18 Cephalon Australia Pty Ltd Anti-il-12/il-23 antibodies
ES2712732T3 (es) * 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
US20100239583A1 (en) * 2009-03-04 2010-09-23 Inotek Pharmaceuticals Corporation Antibodies against flagellin and uses thereof
MX2011009798A (es) 2009-03-20 2011-12-08 Amgen Inc Inmunoglobulinas portadoras y usos de las mismas.
MX2011012299A (es) 2009-05-20 2012-03-29 Novimmune Sa Librerias de polipeptidos sinteticos y metodos para generar variantes de polipeptido naturalmente diversificadas.
CA2773564A1 (en) * 2009-09-14 2011-03-17 Dyax Corp. Libraries of genetic packages comprising novel hc cdr3 designs
US8926976B2 (en) * 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
WO2011038301A2 (en) 2009-09-25 2011-03-31 Xoma Technology Ltd. Screening methods
EP2501407A1 (de) 2009-11-20 2012-09-26 Amgen Inc. Anti-orai1-antigenbindende proteine und ihre verwendung
CA2782333C (en) 2009-12-02 2019-06-04 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen (psma) and methods for their use
KR102024922B1 (ko) 2010-07-16 2019-09-25 아디맵 엘엘씨 항체 라이브러리
SG187787A1 (en) 2010-08-10 2013-03-28 Amgen Inc Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
SG188591A1 (en) 2010-09-22 2013-04-30 Amgen Inc Carrier immunoglobulins and uses thereof
WO2012061074A1 (en) 2010-10-25 2012-05-10 Elan Pharmaceuticals, Inc. METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMAdCAM LEVELS
US20120185956A1 (en) 2011-01-18 2012-07-19 Gingras Jacinthe Global nav1.7 knockout mice and uses
KR20140027174A (ko) 2011-03-24 2014-03-06 옵코 파마슈티칼스, 엘엘씨 비드 또는 입자 기초 라이브러리들, 진단적 키트들을 및 치료제들을 사용한 복합 생물학적 유체에서 바이오마커 발견
KR102148982B1 (ko) 2011-06-03 2020-08-27 조마 테크놀로지 리미티드 Tgf-베타에 특이적인 항체
EP2605014A1 (de) * 2011-12-16 2013-06-19 Merck Patent GmbH Allgemeine Strategie zum Screening von Antikörper-Bibliotheken
EP3050900A1 (de) 2011-12-19 2016-08-03 Xoma (Us) Llc Verfahren zur behandlung von akne
EP2816893A1 (de) 2012-02-22 2014-12-31 Amgen Inc. Aus induzierten pluripotenten stammzellen gewonnene autologe säugetiere und entsprechende verfahren
AU2014232882B2 (en) 2013-03-15 2018-03-22 Hycor Biomedical, Inc. Automated immunoanalyzer system for performing diagnostic assays for allergies and autoimmune diseases
ES2900331T3 (es) 2014-10-15 2022-03-16 Amgen Inc Elementos promotores y reguladores para mejorar la expresión de genes heterólogos en células hospederas
CA3185253A1 (en) 2015-02-02 2016-08-11 Children's Health Care D/B/A Children's Minnesota Anti-surrogate light chain antibodies
WO2016141111A1 (en) 2015-03-03 2016-09-09 Xoma (Us) Llc Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
WO2016161410A2 (en) 2015-04-03 2016-10-06 Xoma Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
JP2018532693A (ja) 2015-08-06 2018-11-08 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー インスリン受容体に対する抗体断片及び低血糖を治療するためのその使用
SG10201913625XA (en) 2015-08-07 2020-03-30 Imaginab Inc Antigen binding constructs to target molecules
WO2017040404A1 (en) * 2015-08-28 2017-03-09 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services A method of detecting molecules in proximity to a target molecule in a sample
EP3490600A1 (de) 2016-08-01 2019-06-05 Xoma (Us) Llc Parathormon-rezeptor 1 (pth1r)-antikörper und verwendungen davon
KR20190057113A (ko) 2016-09-28 2019-05-27 조마 (유에스) 엘엘씨 인터루킨-2에 결합하는 항체 및 그 용도
KR20190078648A (ko) 2016-11-16 2019-07-04 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 건선을 치료하는 방법
JP2020506916A (ja) 2017-01-30 2020-03-05 ヤンセン バイオテツク，インコーポレーテツド 活動性乾癬性関節炎の治療のための抗ｔｎｆ抗体、組成物、及び方法
CA3052578A1 (en) 2017-02-07 2018-08-16 Janssen Biotech, Inc. Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
US11266745B2 (en) 2017-02-08 2022-03-08 Imaginab, Inc. Extension sequences for diabodies
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
MX2020009265A (es) 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
US20200025776A1 (en) 2018-07-18 2020-01-23 Janssen Biotech, Inc. Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
US11548938B2 (en) 2018-08-21 2023-01-10 Quidel Corporation DbpA antibodies and uses thereof
AU2019346134C1 (en) 2018-09-24 2024-06-20 Janssen Biotech, Inc. Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
AU2019383017A1 (en) 2018-11-20 2021-06-03 Janssen Biotech, Inc. Safe and effective method of treating psoriasis with anti-IL-23 specific antibody
US20200197517A1 (en) 2018-12-18 2020-06-25 Janssen Biotech, Inc. Safe and Effective Method of Treating Lupus with Anti-IL12/IL23 Antibody
EP3938384A4 (de) 2019-03-14 2022-12-28 Janssen Biotech, Inc. Herstellungsverfahren zur herstellung von anti-il12/il23-antikörperzusammensetzungen
KR20210141583A (ko) 2019-03-18 2021-11-23 얀센 바이오테크 인코포레이티드 항-il-12/il-23 항체를 사용한 소아 대상의 건선 치료 방법
CA3138241A1 (en) 2019-05-23 2020-11-26 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
JP2023507083A (ja) 2019-12-19 2023-02-21 クイデル コーポレーション モノクローナル抗体融合物
WO2023154305A2 (en) 2022-02-10 2023-08-17 Amgen Inc. Antibody protein product expression constructs for high throughput sequencing

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
WO1987004628A1 (en) * 1986-01-30 1987-08-13 Fred Hutchinson Cancer Research Center Immunoselection method
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE68925366T2 (de) * 1988-11-18 1996-10-31 Univ California Konjugierte polypeptide und verfahren zur herstellung und verwendung
US5196306A (en) * 1989-03-29 1993-03-23 E. I. Du Pont De Nemours And Company Method for the detection or quantitation of an analyte using an analyte dependent enzyme activation system
EP0465577B1 (de) * 1989-03-29 1994-03-16 E.I. Du Pont De Nemours And Company Katalysierte ablagerung von markierungsmittel
US5234820A (en) * 1989-06-30 1993-08-10 Board Of Regents Of The University Of Nebraska Exopeptidase catalyzed site-specific bonding of supports, labels and bioactive agents to proteins
EP0514405B1 (de) * 1990-01-31 1995-01-04 The Upjohn Company Stamm ral-4, nützlich zur herstellung kleiner proteine und peptide
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0617706B1 (de) * 1991-11-25 2001-10-17 Enzon, Inc. Multivalente antigen-bindende proteine
WO1994013804A1 (en) * 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
GB2289677A (en) * 1993-12-06 1995-11-29 Pna Diagnostics As Labelling of nucleic acid analogue-peptide chimerae
US5929049A (en) * 1997-08-08 1999-07-27 Dade Behring Marburg Gmbh Polysaccharide conjugates of biomolecules

Also Published As

Publication number Publication date
GB2315125B (en) 1998-06-03
GB9712818D0 (en) 1997-08-20
US20020004215A1 (en) 2002-01-10
US6489123B2 (en) 2002-12-03
GB2330909A (en) 1999-05-05
DE69735686T2 (de) 2007-04-05
JP3923534B2 (ja) 2007-06-06
GB2315125A (en) 1998-01-21
JP2000517046A (ja) 2000-12-19
EP0906571B1 (de) 2003-04-23
ATE238550T1 (de) 2003-05-15
CA2259421C (en) 2009-06-30
US6342588B1 (en) 2002-01-29
AU3452797A (en) 1998-02-02
EP0906571A1 (de) 1999-04-07
GB2330909B (en) 2000-12-27
CA2259421A1 (en) 1998-01-15
DE69735686D1 (de) 2006-05-24
GB9714397D0 (en) 1997-09-10
US5994519A (en) 1999-11-30
DE69721258T2 (de) 2004-01-29
GB9900205D0 (en) 1999-02-24
WO1998001757A1 (en) 1998-01-15
US6180336B1 (en) 2001-01-30
AU715796B2 (en) 2000-02-10

Similar Documents

Publication Publication Date Title
ATE238550T1 (de) Markierung und auswahl von molekülen
DK0765389T3 (da) Cellesystemer havende specifik interaktion på peptide bindingspar
WO2004042030A3 (en) Displacement sandwich immuno-pcr
EP1499885A4 (de) Neue fusionsproteine und molekulare bindungsassays
ATE238411T1 (de) Verfahren zur lyse von mikroorganismen
ATE341626T1 (de) Membranproteine aus säugetierzellen; verwandte reagentien
EP1111385A3 (de) Enzym-Protein-Komplex
AU2003292425A1 (en) Tagged polyfunctional reagents capable of reversibly binding target substances in a ph-dependent manner
AU1825097A (en) Mammalian cx3c chemokine genes
DE69032062D1 (de) Voraktivierte Proteine zur Markierung von Oligonukleotidsonden
WO2001016170A3 (en) Card proteins involved in cell death regulation
EP1353180A3 (de) Markierung und Auswahl von Molekülen
WO1999047673A3 (en) Isolated mammalian membrane protein genes and related reagents
WO2000018803A3 (en) Antibodies to mammalian langerhans cell antigen and their uses
PT1147419E (pt) Deteccao de celulas utilizando dominios especificos que se ligam as paredes celulares (cbd) de proteinas que se ligam as paredes celulares
WO2003022992A3 (en) Mammalian genes; related reagents
Sano et al. Deoxyribonucleic acids as unique markers in molecular detection
ES8606500A1 (es) Un metodo para determinar la presencia de ige especifica en sueros humanos
Lindbladh Genetically prepared fusion proteins: Applications in analysis and in the study of organized enzyme systems.
WO2001092888A3 (en) A method for screening and isolating microorganisms
ES8606501A1 (es) Un metodo para determinar la presencia de igg especifica en sueros humanos
JPH0882625A (ja) 酵素免疫測定法
ECSP982583A (es) Genes aislados de proteinas de membranas de mamiferos reactivos relacionados

Legal Events

Date Code Title Description
8364 No opposition during term of opposition